| 2026-01-12 | +81.0% | earnings | Seeking Alpha | Biodesix skyrockets 43%, expects FY revenue to beat guidance |
| 2026-01-12 | +81.0% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | +81.0% | earnings | Stock Titan | Lung cancer testing helps Biodesix lift Q4 2025 revenue by 41% - Stock Titan |
| 2026-01-12 | +81.0% | earnings | Quiver Quantitative | Biodesix, Inc. Reports Estimated Q4 2025 Revenue of $28.8 Million, Achieving 41% Growth and Full-Year Revenue of $88.5 Million, Up 24% - Quiver Quantitative |
| 2026-01-12 | +81.0% | news | Stocktwits | This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why - Stocktwits |
| 2026-01-12 | +81.0% | news | StocksToTrade | BDSX Faces Financial Hurdles as Stock Volatility Heightens - StocksToTrade |
| 2026-01-12 | +81.0% | earnings | BizWest | Biodesix sees stock soar after surpassing sales guidance - BizWest |
| 2026-01-12 | +81.0% | earnings | MSN | Biodesix skyrockets 43%, expects FY revenue to beat guidance - MSN |
| 2026-01-12 | +81.0% | news | StocksToTrade | Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade |
| 2026-01-12 | +81.0% | earnings | marketscreener.com | Biodesix, Inc. Provides Earnings Guidance for the Fourth Quarter Ended December 31, 2025 - marketscreener.com |
| 2025-05-13 | -39.5% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2025-05-14 | -39.3% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.08 misses by $0.02, revenue of $18M misses by $3.23M |
| 2025-05-14 | -39.3% | earnings | Seeking Alpha | Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion |
| 2025-05-14 | -39.3% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q1 2025 Earnings Call Transcript |
| 2025-05-14 | -39.3% | executive | simplywall.st | It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year - simplywall.st |
| 2025-11-04 | +36.5% | earnings | Seeking Alpha | Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates |
| 2025-11-04 | +36.5% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript |
| 2025-09-11 | -29.0% | news | Seeking Alpha | Biodesix announces one-for-twenty reverse stock split |
| 2025-09-11 | -29.0% | legal | SEC EDGAR | BDSX 8-K: 8.01 and (SEC Filing) |
| 2025-09-11 | -29.0% | news | Quiver Quantitative | Biodesix, Inc. Announces One-for-Twenty Reverse Stock Split Effective September 15, 2025 - Quiver Quantitative |
| 2025-09-11 | -29.0% | news | Yahoo Finance | Biodesix Announces One-for-Twenty Reverse Stock Split - Yahoo Finance |
| 2026-04-22 | -23.1% | news | Zacks | Are Medical Stocks Lagging Aura Biosciences (AURA) This Year? |
| 2025-03-04 | +22.1% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q4 2024 Earnings Call Transcript |
| 2025-03-04 | +22.1% | news | Yahoo Finance | Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025 - Yahoo Finance |
| 2021-08-10 | -21.2% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | +19.6% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.49 beats by $0.38, revenue of $28.7M beats by $2.45M |
| 2026-02-26 | +19.6% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | +19.6% | earnings | Yahoo Finance | Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance |
| 2024-11-01 | -18.4% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript |
| 2024-11-01 | -18.4% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.07 beats by $0.01, revenue of $18.2M misses by $0.32M |
| 2024-11-01 | -18.4% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2022-04-11 | +17.0% | legal | SEC EDGAR | BDSX 8-K: 1.01, 3.02and8.01 (SEC Filing) |
| 2026-01-14 | -15.5% | earnings | simplywall.st | Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump - simplywall.st |
| 2025-01-10 | -14.8% | earnings | Seeking Alpha | Biodesix estimates Q4 revenue above consensus |
| 2025-01-10 | -14.8% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2021-11-15 | -14.8% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2025-01-08 | -13.4% | news | Yahoo Finance | BDSX Stock Rises After Publication of Study Data for Nodify CDT Test - Yahoo Finance |
| 2026-04-21 | -12.4% | news | Zacks | LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock? |
| 2025-11-03 | +12.3% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$1.16 beats by $0.35, revenue of $21.8M beats by $0.82M |
| 2025-11-03 | +12.3% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2025-11-03 | +12.3% | earnings | Yahoo Finance | Biodesix Inc (BDSX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Costs - Yahoo Finance |
| 2024-04-09 | -11.9% | legal | SEC EDGAR | BDSX 8-K: 1.01, 3.02, 5.03, 8.01 (SEC Filing) |
| 2026-02-27 | +11.2% | earnings | Seeking Alpha | Biodesix outlines $106M–$112M 2026 revenue target as sales expansion drives 41% Q4 growth |
| 2026-02-27 | +11.2% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript |
| 2021-05-11 | -10.3% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-04-13 | -9.7% | news | Zacks | Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study |
| 2022-10-11 | -9.6% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2023-03-06 | -9.5% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2022-12-16 | +9.0% | legal | SEC EDGAR | BDSX 8-K: 5.02, 7.01 (SEC Filing) |
| 2023-11-07 | -8.6% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.14 beats by $0.01, revenue of $13.5M misses by $0.85M |
| 2023-11-07 | -8.6% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-04-23 | -8.5% | news | Exec Edge | SkylineDx Presents Gene Expression Profiling for Skin Cancer Metastases |
| 2023-11-11 | +8.4% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q3 2023 Earnings Call Transcript |
| 2022-05-11 | -8.4% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-04-09 | -8.4% | legal | GlobeNewswire | Biodesix Recognized as a Top Workplace for Third Consecutive Year |
| 2026-04-09 | -8.4% | news | Zacks | Here's Why You Should Retain DaVita Stock in Your Portfolio for Now |
| 2026-04-09 | -8.4% | news | Stock Titan | Employees put Biodesix on USA TODAY's Top Workplaces list for a third year - Stock Titan |
| 2026-04-09 | -8.4% | news | Stock Titan | Biodesix (NASDAQ: BDSX) outlines 2026 virtual meeting, board and pay votes - Stock Titan |
| 2023-05-11 | -8.2% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2024-04-05 | -7.7% | news | Seeking Alpha | Biodesix prices its 17.4M shares offering at $1.15 apiece |
| 2025-04-17 | -7.5% | legal | SEC EDGAR | BDSX 8-K: 5.02 (SEC Filing) |
| 2026-04-14 | -7.3% | legal | Zacks | MDLN Gets FDA Warning for Quality Lapses in Angiographic Syringes |
| 2026-01-26 | -6.5% | news | Investing.com | Biodesix (BDSX) emeritus director Schuler buys $903k in stock - Investing.com |
| 2024-01-31 | +6.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-03-03 | -6.3% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.06 beats by $0.01, revenue of $20.42M beats by $0.5M |
| 2025-03-03 | -6.3% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2025-10-22 | -5.9% | news | Stock Titan | Biodesix (NYSE: BDSX) to validate ddPLEX ESR1 assay; IVD filings and CLIA-CAP service - Stock Titan |
| 2021-12-08 | -5.8% | legal | SEC EDGAR | BDSX 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-01-04 | -5.6% | legal | SEC EDGAR | BDSX 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-03-19 | -5.6% | news | Yahoo Finance | Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance |
| 2022-03-14 | -5.0% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2022-11-21 | +4.7% | legal | SEC EDGAR | BDSX 8-K: 1.01, 1.02, 2.03, 3.02, 8.01 (SEC Filing) |
| 2026-04-06 | -4.1% | news | Stock Titan | Cancer test developer Biodesix brings 7 studies to AACR meeting - Stock Titan |
| 2026-04-06 | -4.1% | news | qz.com | Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year? - qz.com |
| 2025-09-04 | +4.0% | news | simplywall.st | Biodesix Insiders Added US$3.58m Of Stock To Their Holdings - simplywall.st |
| 2023-07-26 | -3.9% | legal | SEC EDGAR | BDSX 8-K: 8.01 and (SEC Filing) |
| 2026-03-11 | +3.9% | news | Seeking Alpha | Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript |
| 2023-06-06 | +3.7% | legal | SEC EDGAR | BDSX 8-K: 5.02 and (SEC Filing) |
| 2026-04-02 | +3.5% | news | Stock Titan | Biodesix (BDSX) chair adds 1,361 shares through RSU exercise - Stock Titan |
| 2025-11-05 | +3.2% | analyst | Yahoo Finance | US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results - Yahoo Finance |
| 2025-11-05 | +3.2% | analyst | simplywall.st | US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results - simplywall.st |
| 2026-04-01 | +3.1% | earnings | MarketBeat | Biodesix, Inc. (NASDAQ:BDSX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat |
| 2021-06-05 | -2.8% | news | Moomoo | Biodesix(BDSX) Stock Price Today | Quotes & News - Moomoo |
| 2024-08-08 | -2.8% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q2 2024 Earnings Call Transcript |
| 2026-03-03 | -2.7% | news | Yahoo Finance | Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance |
| 2022-11-03 | +2.5% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2025-08-10 | -2.5% | earnings | Yahoo Finance | Earnings Release: Here's Why Analysts Cut Their Biodesix, Inc. (NASDAQ:BDSX) Price Target To US$1.80 - Yahoo Finance |
| 2025-08-09 | -2.5% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript |
| 2022-09-01 | -2.4% | analyst | TradingView | BDSX Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-04-16 | +2.3% | news | Zacks | Here's Why You Should Add DexCom Stock to Your Portfolio Now |
| 2025-08-07 | +2.1% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.08 misses by $0.01, revenue of $20M beats by $1.53M |
| 2025-08-07 | +2.1% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2024-05-10 | -2.1% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q1 2024 Earnings Call Transcript |
| 2026-04-17 | -2.1% | news | Simply Wall St. | How Recent Shifts Are Reframing The Biodesix (BDSX) Investment Story |
| 2026-01-27 | +2.0% | news | Investing.com | Biodesix director Schuler buys $1.1m+ in BDSX stock - Investing.com |
| 2026-01-27 | +2.0% | news | Quiver Quantitative | Insider Stock Purchases: January 27, 2026 - Quiver Quantitative |
| 2026-01-27 | +2.0% | news | Insider Monkey | Hedge Fund and Insider Trading News: Seth Klarman, Dan Loeb, Michael Burry, Michael Platt, Bridgewater Associates, Greenlight Capital, Biodesix Inc (BDSX), UWM Holdings Corp (UWMC), and More - Insider Monkey |
| 2025-10-01 | +1.5% | legal | SEC EDGAR | BDSX 8-K: 8.01 (SEC Filing) |
| 2024-08-07 | +1.5% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.08 beats by $0.01, revenue of $17.9M beats by $1.76M |
| 2024-08-07 | +1.5% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2025-10-29 | +1.4% | news | The Business Journals | Louisville company rings Nasdaq bell after regaining listing compliance - The Business Journals |
| 2026-04-20 | -1.4% | news | GlobeNewswire | Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026 |
| 2026-04-20 | -1.4% | earnings | Stock Titan | Biodesix plans May 4 Q1 results release, 4:30 p.m. ET webcast - Stock Titan |
| 2022-03-07 | -1.3% | legal | SEC EDGAR | BDSX 8-K: 1.01, 8.01 (SEC Filing) |
| 2022-02-14 | -1.3% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-02-23 | -1.0% | executive | Investing.com | Cowie, Biodesix CFO, sells $6834 in BDSX stock - Investing.com |
| 2023-08-07 | +0.8% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q2 2023 Earnings Call Transcript |
| 2023-08-07 | +0.8% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.17 beats by $0.04, revenue of $11.9M beats by $0.25M |
| 2023-08-07 | +0.8% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-04-10 | -0.6% | earnings | MarketBeat | Aberdeen Group plc Takes $1.78 Million Position in Biodesix, Inc. $BDSX - MarketBeat |
| 2024-05-08 | -0.6% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.14, revenue of $14.8M |
| 2024-05-08 | -0.6% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2022-08-04 | +0.4% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-02-24 | -0.3% | news | Stock Titan | Biodesix management to speak at TD Cowen and Barclays events - Stock Titan |
| 2023-01-10 | -0.3% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Biodesix (BDSX) - Zacks Investment Research |
| 2024-03-01 | -0.2% | earnings | Seeking Alpha | Biodesix, Inc. (BDSX) Q4 2023 Earnings Call Transcript |
| 2024-03-01 | -0.2% | earnings | Seeking Alpha | Biodesix GAAP EPS of -$0.10, revenue of $14.7M |
| 2024-03-01 | -0.2% | legal | SEC EDGAR | BDSX 8-K: 2.02 and (SEC Filing) |
| 2026-04-26 | — | analyst | MSN | Wall Street analysts see an 86.45% upside in Biodesix (BDSX): Can the stock really move this high? - MSN |
| 2026-04-26 | — | earnings | MarketBeat | Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat |
| 2026-04-24 | — | news | ChartMill | BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill |
| 2026-04-24 | — | news | MEXC Exchange | BDSX Price Today: Biodesix, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange |